Patents by Inventor Hideo Kubo

Hideo Kubo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030218850
    Abstract: Plural CPUs 20-1 through 20-6 are mounted on a circuit board 11, and heat sinks 30-1 through 30-6 are mounted on these CPUS, respectively. The CPUs 20-1 through 20-6 are cooled by an air flow generated by motor fan units 14-1, 14-2, 15-1, and 15-2. The CPUs 20-1 through 20-6 are arranged such that a ratio of a sectional clearance area at the downstream side of the air flow to a sectional area of a tunnel 12 is lower than a corresponding ratio at the upstream side of the air flow. This clearance is formed between a cover member 13 and the heat sinks 30-1 through 30-6. Air flow passages 85 and 86 are formed at both sides at the upstream side. By the air flow passages 85 and 86, the amount of fresh air that is sent to the heat sinks 30-5 and 30-6 at the downstream side is increased. Accordingly, the cooling of the CPUs 20-5 and 20-6 at the downstream side is promoted compared to the conventional case.
    Type: Application
    Filed: June 11, 2003
    Publication date: November 27, 2003
    Applicant: FUJITSU LIMITED
    Inventors: Hideo Kubo, Masahiro Suzuki
  • Patent number: 6498139
    Abstract: The present invention provides methods of inhibiting or sequestering 14-3-3 protein from binding to the insulin receptor substrate −1 or −2 by administering a substance which inhibits the interaction of these two proteins.
    Type: Grant
    Filed: March 29, 2000
    Date of Patent: December 24, 2002
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Yoshio Yazaki, Tomoichiro Asano, Hideo Kubo, Akira Kanda
  • Publication number: 20020132759
    Abstract: The present invention relates to a remedy for diseases caused by insulin resistance, which comprises, as an active ingredient, a substance exhibiting activity for inhibiting the binding of the full-length insulin receptor substrate-1 (IRS-1) or insulin receptor substrate-2 (IRS-2) or a portion of the same to the full-length 14-3-3 protein or a portion of the same; and to a screening method for a remedy for diseases caused by insulin resistance, which comprises assaying the activity for inhibiting the binding.
    Type: Application
    Filed: March 1, 2002
    Publication date: September 19, 2002
    Applicant: DAIICHI PHARMACEUTICAL CO., LTD.
    Inventors: Yoshio Yazaki, Tomoichiro Asano, Hideo Kubo, Akira Kanda
  • Publication number: 20010020365
    Abstract: A refrigeration system allows the refrigerant to circulate through a closed circulation channel. A dry evaporator is incorporated in the circulation channel. The dry evaporator is designed to keep a quality smaller than 1.0 in evaporating the refrigerant. The quantity of heat transfer per unit area, namely, a heat transfer coefficient depends on the quality. The heat transfer coefficient remarkably drops when the quality of the refrigerant exceeds a predetermined threshold level before the quality actually reaches 1.0. The quality of the refrigerant kept below the predetermined threshold level during vaporization of the refrigerant in the dry evaporator allows a reliable establishment of a higher performance of cooling. On the other hand, if a refrigerant completely evaporates in a dry evaporator in a conventional manner, the heat transfer coefficient of the refrigerant remarkably drops after the quality of the refrigerant exceeds the predetermined threshold level.
    Type: Application
    Filed: December 28, 2000
    Publication date: September 13, 2001
    Inventors: Hideo Kubo, Hisashi Kawashima, Jie Wei, Junichi Ishimine, Masahiro Suzuki, Yoshiaki Udagawa, Masahiro Mochizuki
  • Patent number: 5418232
    Abstract: A compound of formula (I) possesses excellent potassium channel opening activity and is effective on various diseases arising from contractions of blood vessels, bronchial smooth muscles, etc., for example, ischemic heart diseases exemplified by angina pectoris, asthma, pollakisuria, sequela of subarachnoid hemorrhage, peripheral arterioinfarct, and so on. The compound has potent and long-lasting antihypertensive activity, with the onset of the action being slow, excellent activity in increasing renal blood flow, and high safety, and is therefore particularly useful as an antihypertensive. ##STR1## The substituents are as defined in the specification.
    Type: Grant
    Filed: May 12, 1993
    Date of Patent: May 23, 1995
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Tetsuya Mimura, Hideo Kubo